Effect of medication produced with cysts of Toxoplasma gondii in mice infected with this protozoan
Keywords:
Toxoplasmosis, Toxoplasma gondii, biotherapy, TGF-beta.Abstract
Under test blind, controlled, randomized by draw, the effect of different potencies of T. gondii biotherapic were compared. Fifty-six male mice, Swiss, 60 days-old, were divided into groups according to the treatment: BIOT-TG7, BIOT-TG17, BIOT-TG30, TG60-BIOT, BIOT-TG100, TG200-BIOT, GCInf-infected control group treated with grain alcohol and BCM-7% - non treated and non infected. The biotherapics were produced according to the Brazilian Homeopathic Pharmacopoeia, with macerated mouse brain (20 cysts T. gondii/100μL). The animals were treated for three consecutive days prior to infection. Groups BIOT-TG7, BIOT-TG17, BIOT-TG30 and BIOT-TG60 and GCInf 0.1mL/4X/day received on the first day and 2X/day on the other days of treatment. For BIOT -TG100 and BIOT- TG200 were used 0.1mL/single dose / day. After 60 days the animals were infected (ME49 strain 20-T gondii cysts), orally. Fundoscopy and ocular tononetry were conduced at 55 days post-infection. Sixty days after infection the number of cysts were counted and serum TGF-β (ELISA) were dosed . For statistical comparison were used the Kruskal-wallis test, 5% statistical significance and Effect Size Measures. In tonometry, there was no significant difference between the control group and the other groups. Regarding to ocular fundoscopy, it was found that 80% of group BIOT-TG100 did not present amendments and 20% presented mild subretinal hemorrhage surrounding the optic nerve differently from the other groups. In BIOT-TG200 group, 50% of the animals presented mild hemorrhage and 50% remained unchanged. The BIOT-TG200 presented a decrease in the number of cysts in the brain. There was no difference observed between the BIOT-TG100 and the control group. Animal group BIOT-TG100 presented higher (p <0.01) concentrations of TGF-ï¢ in comparison to BIOT-TG200 group. The highest dilutions BIOT-TG100 and BIOT-TG200 provided more effective benefits, although the levels of TGF-ï¢ have changed in opposite ways in the two treatments. This result deserves further studies.Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Caroline Felicio Braga, Denise Lessa Aleixo, Neide Martins Moreira, Ricardo Nascimento Drozino, Franciele Karina da Veiga de Sales, Carina Ribeiro Lopes, Camila Fernanda Brustolin, Paula Fernanda Massini, Silvana Marques de Araújo
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
<a rel="license" href="http://creativecommons.org/licenses/by-nc-sa/4.0/"><img alt="Creative Commons License" style="border-width:0" src="https://i.creativecommons.org/l/by-nc-sa/4.0/88x31.png" /></a><br />This work is licensed under a <a rel="license" href="http://creativecommons.org/licenses/by-nc-sa/4.0/">Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License</a>.